{Reference Type}: Journal Article
{Title}: Quantification of the contribution of individual coagulation factors to haemostasis using a microchip flow chamber system and reconstituted blood from deficient plasma.
{Author}: Fuchizaki A;Yasui K;Hayashi T;Fujimura Y;Oyamada C;Ohnishi-Wada T;Hosokawa K;Shimogaki K;Kimura T;Hirayama F;Takihara Y;
{Journal}: Vox Sang
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 1
{Factor}: 2.996
{DOI}: 10.1111/vox.13709
{Abstract}: <B>OBJECTIVE: </B>Quantifying the contribution of individual coagulation factors to haemostasis may aid our understanding of the haemostatic function in patients with rare coagulation deficiencies (RCDs) and the exploration of suitable treatments.<BR><B>METHODS: </B>Reconstituted blood prepared from specific coagulation factor-deficient plasma (factor [F]II; prothrombin, FV, FVII, FVIII, FIX, FX, FXI or FXII) and red blood cell/platelet products were used to simulate the whole blood of patients with RCD. We prepared in vitro treatment models for patients with prothrombin deficiency using coagulation factor agents and fresh frozen plasma. Haemostatic function was measured using a microchip flow chamber system at 600 s-1.<BR><B>RESULTS: </B>The haemostatic function was low, especially in blood samples reconstituted with prothrombin- and FX-deficient plasma. In a plasma transfusion model of prothrombin deficiency, haemostatic function recovered after 10% replacement with normal plasma and reached a plateau at ≧60% replacement. A treatment model of prothrombin deficiency with prothrombin complex concentrates revealed dose-dependent therapeutic effects in the range of 0-50 IU/kg.<BR><B>CONCLUSIONS: </B>Microchip flow chamber system-based quantification of haemostatic function using reconstituted blood could predict haemostasis and therapeutic effects of treatments in patients with prothrombin deficiency.